Nanoneedle technology licensed for early disease detection, biomarker discovery, and more

[Mij]

A Boston-based startup company, NanoMosaic LLC, intends to commercialize a high-throughput, high-sensitivity platform for analyte detection developed at Harvard University. Through an exclusive license agreement with Harvard Office of Technology Development, NanoMosaic is developing screening tools based on functionalized ‘nanoneedles’ that may aid in a number of biomedical fields including the early detection of disease, prognostic monitoring, and biomarker discovery.

The potential applications also include infectious disease monitoring, including for COVID-19, as the platform could be used to measure antibody levels in patient samples over time, providing important information on the development of, or decline in, a patient’s immunity to the novel coronavirus.

https://otd.harvard.edu/news/nanone...for-early-disease-detection-biomarker-discov/

 

[Forbin]

It sounds somewhat like "VirScan," a nanotechnology that also came out of Harvard around 2015 that was said to be able to reveal your entire history of viral infections from a single drop of blood. This newer technology seems like it might be even more sensitive.

This would be different from the nanoneedle tech being developed at Stanford University, which, so far as I know, measures electrical impedance.

 

[Sly Saint]

Harvard research

Caroline Ferguson is a fourth year PhD student in the Department of Bioengineering and a member of the Lab of Micro- and Nanotechnology Diagnostics and Biology (led by associate professor Xuanhong Cheng). In this video, Ferguson talks about her research into improving the diagnosis of both cancer and chronic fatigue syndrome, and the very personal reason that motivates her work.

https://engineering.lehigh.edu/news...caroline-ferguson-improving-disease-diagnosis

(video is from 2021)

 

[Mij]

Would love to find her on Twitter.

 

[Mij]

NonoMosaic Unveils a Method to Enable Proteomics by Combining Aptamers and Antibodies on it's MosaicNeedle Platform at 2022 AACR

"Enabling both aptamers and antibodies as the affinity probes and demonstrating high performance with both reagents on the Tessie™ instrument paves the way to accurately measure the expression of one or more proteoforms of every protein-coding gene", said Qimin Quan, Chief Scientific Officer of NanoMosaic, "The ultra-high plexing capability allows proteome-level detection with low sample volume requirement and at high throughput. The simple workflow makes it easy for scientists to develop home-brew assays on high-value targets from the discovery phase." Quan concluded.


https://finance.yahoo.com/news/nanomosaic-unveils-method-enable-proteomics-124700025.html

https://www.prnewswire.com/news-rel...aicneedle-platform-at-2022-aacr-301516671.htm